leisure time -WSS

leisure time

author：leisure time 2025-08-12 08:29:17 - browse：997

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Liver decline slowed by off

Wikipedia

WSS

Hospitals struggle to profit from CAR

EF3 tornado rips through North Carolina amid extreme weather nationwide

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Hospitals struggle to profit from CAR

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Why Congress must ban federal programs from using QALYs

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Medical leaders decry Supreme Court decision on affirmative action

Awakening the world to the whoosh: A patient's crusade

The high cost of giving birth even with insurance

Reports of telehealth's death have been greatly exaggerated

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Hepatitis C has a cure — but many Americans still lack access to it

Judge rejects Trump's request to move Stormy Daniels hush

Wikipedia

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Questions and answers about ramping up H5N1 bird flu vaccine

Why Congress must ban federal programs from using QALYs

As a primary care physician, here's how I hope to partner with AI

Driven by the pandemic, applicants flood public health schools

Tocagen's brain cancer gene therapy trial continues. Investors worry

explore

Wikipedia

knowledge

entertainment